Analysts Offer Insights on Healthcare Companies: Phasebio Pharmaceuticals Inc (PHAS), Zafgen (ZFGN) and HTG Molecular Diagnostics (HTGM)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phasebio Pharmaceuticals Inc (PHAS), Zafgen (ZFGN) and HTG Molecular Diagnostics (HTGM).

Phasebio Pharmaceuticals Inc (PHAS)

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Phasebio Pharmaceuticals Inc. The company’s shares closed yesterday at $13.23.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.6% and a 49.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Rocket Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

The the analyst consensus on Phasebio Pharmaceuticals Inc is currently a Moderate Buy rating.

See today’s analyst top recommended stocks >>

Zafgen (ZFGN)

In a report released yesterday, Yaron Werber from Cowen & Co. maintained a Hold rating on Zafgen. The company’s shares closed yesterday at $2.61, close to its 52-week low of $2.33.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 13.8% and a 62.2% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zafgen with a $7 average price target.

HTG Molecular Diagnostics (HTGM)

Cantor Fitzgerald analyst Jordan Abrams reiterated a Buy rating on HTG Molecular Diagnostics yesterday and set a price target of $6. The company’s shares closed yesterday at $2.48, close to its 52-week low of $2.03.

Abrams noted:

“. We reiterate our Overweight rating and 12-month PT of $6 on HTGM shares. We see a positive readout in either PDP program as the nearest significant potential catalyst to shares, and we continue to think HTG will see strength in its underlying product-based business. HTG reported 1Q19 revenue of $3.2MM (-32%) ahead of FactSet consensus by $0.5MM. Management reiterated its 2019 revenue expectations of $23-$28MM (+19% at the mdpt). The slight 1Q beat was driven by strong revenue in HTG’s base RUO profiling business and newly contributing molecular diagnostic product business. We are still awaiting results from PDP 2 and PDP 3, which are expected to read out within the next quarter or two.”

According to TipRanks.com, Abrams is ranked #4379 out of 5185 analysts.

HTG Molecular Diagnostics has an analyst consensus of Strong Buy, with a price target consensus of $6.33, a 155.2% upside from current levels. In a report issued on May 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $8 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts